STOCK COMMENTS / EPS CHANGESBlackRock (BLK) target raised at Jefferies t o $198, Jefferies said. ETF fee cuts less than feared. Hold rating.
Citigroup (C - Get Report) estimates, target boosted at JMP. Shares of C now seen reaching $26, according to JMP Securities. Estimates also upped, given higher expected mortgage production. Underperform rating.
Clean Harbors (CLH) estimates, target cut at JP Morgan. CLH estimates were reduced through 2013, JP Morgan said. Company is leveraged to bad weather and lower rental equipment usage. Overweight rating and new $65 price target.
Costco (COST - Get Report) estimates, target raised at Guggenheim. Shares of COST now seen reaching $98, according to Guggenheim. Estimates also increased, as the company is cutting costs and seeing higher membership income.Discovery (DISCA) estimates, target increased at Lazard. DISCA estimates were raised through 2013, Lazard said. Company can continue to deliver above-average audience growth. Buy rating and new $77 price target. Gannett (GCI) numbers raised at UBS. Shares of GCI now seen reaching $19, UBS said. Estimates also raised on strong publishing / broadcast. Neutral rating. Microchip Technology (MCHP) numbers lowered at Jefferies. Shares of MCHP now seen reaching $38, Jefferies said. Estimates also lowered on negative pre-announcement. Buy rating. Microchip estimates, target cut at Credit Suisse. Shares of MCHP now seen reaching $38, according to Credit Suisse. Estimates also reduced, given the company's new guidance. Outperform rating. Microsoft (MSFT) estimates, target cut at MKM. Shares of MSFT now seen reaching $32, according to MKM Partners. Estimates also reduced, Company is seeing slower Windows growth. Neutral rating. NetApp (NTAP) target cut at UBS to $40.50, UBS said. Inexpensive, but faces long term challenges. Buy rating. Sirius XM (SIRI) added to US 1 List at BofA/Merrill. Company can deliver solid, visible and predictable operating growth. Tenneco (TEN) numbers lowered at Jefferies. T Shares of TEN now seen reaching $34, Jefferies said. Estimates also lowered on weakness in Global CV and Europe. Buy rating. Teva (TEVA) estimates, target reduced at Canaccord. TEVA estimates were cut through 2013, Canaccord Genuity said. Company is facing a lower US generic outlook. Buy rating and new $50 price target. >To submit a news tip, email: firstname.lastname@example.org.
Twitter and become a fan on Facebook.